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schedules. With a low estimated a/b ratio, a larger dose per fraction would be beneficial, with moderate fractionationophisticated delivery techniques and changing fractionation
schedules rapidly becoming a standard of care. The integration of a magnetic resonance imaging (MRI) scanner and
linear accelerator allows for accurate soft tissue tracking with the capacity to replan for the anatomy of the day. Extreme
hypofractionation schedules become a possibility using the potentially automated steps of autosegmentation, MRI-only
workflow, and real-time adaptive planning. The present report reviews the steps involved in hypofractionated adaptive
MRI-guided prostate radiation therapy and addresses the challenges for implementation.  2017 The Authors. Published
by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Prostate radiation therapy (RT) techniques have under-
gone a metamorphosis during the past 2 decades. We have
transitioned from 2-dimensional to 3-dimensional (3D)
techniques and, subsequently, to intensity modulated RT,
image-guided RT (IGRT), and, more recently, to stereo-
tactic body RT (SBRT). Localization strategies have
evolved from external skin markings, to 2-dimensional/
megavoltage-based bony localization, to complex tech-
niques allowing localization of the target through
implanted fiducial markers, electromagnetic beacons, or
3D/kilovoltage volumetric imaging with soft tissue capa-
bilities of in-room computed tomography (CT) or cone
beam CT.
However, another wave of technological refinements is
fast approaching, with magnetic resonance imaging
(MRI)-guided photon RT, modern particle therapy, and
the prospect of ultrafast replanning, enabling treatment
paradigms previously thought to be science fiction to
become reality.
The improvement in precision delivered by these
technical changes has synchronized with a change in our
RT fractionation. The CHHiP (conventional or hypo-
fractionated high dose intensity modulated radiotherapy
for prostate cancer) trial (1) has shown that 60 Gy in
20 fractions is at least as good as 74 Gy in 37 fractions,
which has changed the standard fractionation in many
countries from 7.5 weeks to 4 weeks. The PACE (prostate
advances in comparative evidence) trial (ClinicalTrials.
gov identifier, NCT01584258) is randomizing between
a similar 4-week schedule and 5-fraction SBRT. As the
a/b ratio of prostate cancer is thought to be low
(2-5), hypofractionation should improve the therapeutic
ratio.
The purpose of the present review is to describe
1. The future implications of the existing evidence on the
optimal fractionation for prostate cancer and, ultimately,
whether single-fraction RT is feasible
2. How MRI-guided RT (MRgRT) could change the para-
digms in prostate cancer RT
3. A road map to overcoming the obstacles to implementationSearch Strategy and Selection Criteria
Published studies for the present review were identified by
conducting a search using PubMed, with the following words:
“prostate,” “radiotherapy,” “radiation therapy,” “MRI,” “MR,”
“magnetic resonance image,” “adaptive,” “MR-guided,” “MR-
linac,” “ViewRay,” “autosegmentation,” “automatic segmen-
tation,” “autocontouring,” “pseudo-CT,” and “substitute CT.”
The last PubMed search was performed on August 1, 2017.
The search included meeting abstracts and was restricted to
reports available in English. Further references were identified
by a manual search of the reference list of the included
studies. Identified studies were first screened by title and/or
abstract, with a further full paper screening to generate the
final list of studies relevant to the scope of the present review.
HypofractionationdHow Low Do We Go?
Although the ideal dose and fractionation of RT, allowing
for maximum tumor control with acceptable toxicity, is far
from certain, hypofractionation is increasingly favored (6-
8). The a/b ratio for prostate cancer is estimated to be as
low as 1.5 Gy (1, 2, 9, 10), suggesting that moderate
hypofractionation can be as effective as standard fraction-
ation for prostate RT. This has now been confirmed in large
phase III trials (1, 11).
Extreme hypofractionation, using SBRT doses per
fraction of 7.0 Gy, has many potential advantages,
including improved clinical outcomes and fewer visits,
improving patient convenience and departmental capacity.
Prospective phase II studies of SBRT have focused on low-
and intermediate-risk patients but have reported favorable
biochemical outcomes for all risk groups (12, 13). The
phase III PACE trial is testing 5-fraction SBRT against
standard fractionation to establish whether the abbreviated
schedule is noninferior. In advance of the randomized ev-
idence, SBRT in 5 fractions appears to have promising
efficacy and side effect profile.
To enhance personalized treatment, the dose can be
escalated to the dominant intraprostatic lesion, which is the
most common site of local recurrence (14, 15). This has
been tested in the FLAME (investigate the benefit of a focal
Volume 100  Number 2  2018 MR-guided adaptive RT for prostate treatment 363lesion ablative microboost in prostate cancer) trial
(ClinicalTrials.gov identifier, NCT01168479) (16) and the
hypo-FLAME (hypofractionated focal lesion ablative
microboost in prostate cancer) study (ClinicalTrials.gov
identifier, NCT02853110). The concept of “biological
conformality” (17) uses the additional information from
functional sequences to target the dose to the area most
likely to benefit from dose escalation. In particular, diffu-
sion weighted imaging (DWI) can be used to generate
apparent diffusion coefficient maps to identify more
aggressive disease, which might benefit from boosting
(18-20).
The direction has been towards progressively more
abbreviated RT schedules; thus, if 5-fraction SBRT is safe
and effective, it raises the question of how low can we go
(Fig. 1). Hoskin et al (21, 22) reported the longer term
outcomes for mainly intermediate- and high-risk patients
who underwent high-dose-rate brachytherapy (HDR-BT)
alone. A dose of either 3 fractions at 10.5 Gy or 2 fractions
at 13 Gy gave acceptable toxicity rates, with 91% to 93%
free of biochemical relapse at 4 years (22). The same group
reported early toxicity data showing single-fraction prostate
HDR-BT with 19 Gy is tolerable, although a significant in-
crease in the need for catheterization was seen compared
with the 2-fraction cohort, in particular, when 20 Gy was
delivered to the whole gland (23). However, late toxicity and
biochemical control were similar for a single 19- to 20-Gy
fraction compared with 2 to 3 fractions (22). Other groups
have reported favorable toxicity rates with single-fraction
HDR-BT (24, 25). Prada et al (24) reported low
morbidity in patients treated with single-fraction 19-Gy
HDR-BT monotherapy with injections of transperineal
hyaluronic acid into the perirectal fat. However, no margin
was added to the prostate for the planning target volume,
and the biochemical control rate was 66% at 6 years. The
urethral dose can be a limiting factor to the total dose
achieved, as seen when HDR-BT is used to plan an intra-
prostatic boost (26).
Low-dose-rate brachytherapy is also an option for dose
escalation, with low toxicity rates and excellent biochem-
ical control (27, 28) and without the need for a shielded
room such as required for HDR-BT. In the ASCENDE-RTCHHiP
60 Gy in
20
fractions
PACE
36.25 Gy
in 5
fractions
? Where
next
RT01
74 in 37
fractions
Fig. 1. Progression of radiation therapy trials within the
United Kingdom during the past 15 years. Abbreviations:
CHHiP Z conventional or hypofractionated high dose in-
tensity modulated radiotherapy for prostate cancer;
PACE Z prostate advances in comparative evidence;
RT01 Z Medical Research Council RT01.(an analysis of survival endpoints for a randomized trial
comparing a low-dose-rate brachytherapy boost to a dose-
escalated external beam RT) trial, the use of low-dose-
rate BT as a boost improved biochemical progression-free
survival compared with dose-escalated external beam RT
alone (29); however, this was at the cost of higher genito-
urinary toxicity (30). Although brachytherapy might be
considered the ultimate in conformal treatment, it is inva-
sive and requires patients to meet anatomic criteria and is
therefore not broadly available to all patients. In contrast,
linear accelerator (linac)-based single-fraction treatment
would potentially be feasible across the globe. It might
even offer cost-effective benefits compared with brachy-
therapy or multiple-fraction treatment and allow higher
patient throughput on a single machine.
It is technically feasible to deliver similar target doses
and meet the same constraints of HDR-BT using external
beam RT (31). SBRT can be used to deliver an equivalent
biologically effective dose without the need for a surgical
procedure, general anesthesia, and associated potential
complications. This is being assessed within the phase II
PROSINT (phase II study of ultra-high-dose hypo-
fractionated vs single-dose image-guided radiotherapy
for prostate cancer) trial (ClinicalTrials.gov identifier,
NCT02570919) randomizing between 45 Gy in 5 frac-
tions and a single 24-Gy fraction.
Given the higher dose per fraction, highly conformal
dose distribution, and steep dose gradient seen with SBRT,
accurate delivery using direct tumor motion monitoring and
online adaptive RT (ART) methods has become even more
important. The ideal delivery system would consist of
optimal image guidance (before treatment and intrafraction
MRI), rapid delivery, and intrafraction ART.Future of Image-Guided RT
MRgRT Platforms
MRgRT systems provide what has long been considered the
“holy grail” of RT delivery, the integration of an MRI scanner
that can provide clinical quality imaging with a modern linear
accelerator (32). Several systems are in development for
clinical use (33-36); these have been summarized in Table 1.
Not only can the improved soft tissue contrast of MRI
improve patient positioning before RT “on-line,” but “real-
time” imaging during treatment delivery itself can also help to
detect the tumor and normal tissue position and deliver the
radiation dose more precisely.
The MRIdian system (ViewRay Inc, Oakwood Village,
OH), with integrated options of either tricobalt-60 or, more
recently, a 6-megavoltage linac, has been treating patients
since 2014, and the first patient was treated using the Elekta
MR-Linac (Elekta AB, Stockholm, Sweden) in May 2017.
Despite the potential effect on dose distribution by the mag-
netic field (37), which increases with higher field strength
(38), treatment plan quality equivalency to standard linacs is
Table 1 Magnetic resonance imaging-guided radiation platforms existing or in development
Variable Type of system
Magnetic field
orientation
Research/
clinical status Adaptive capabilities
Elekta
MR-Linac (29)
1.5-T, 7-MV; 70-cm closed
bore; single-focused
Agility MLC providing
5-mm resolution for
nominal 100-cm SSD,
projecting to 7 mm at the
isocenter
B0 magnetic field
perpendicular to
delivery
First patient treated
May 2017 in
Utrecht as part of
First In Man
protocol
ART capabilities include
1. Shifting plan to overlay
anatomydsimple dose shift
2. Offline ART
3. Library of plans
4. Online ARTdsegment-weight
optimization and full
reoptimization available
5. Visual tracking of target
ViewRay MRIdian
cobalt-60
system (30)
0.35-T Cobalt system, 3
60Co heads on rotating
gantry ring; split magnet
70-cm closed bore
B0 magnetic field
perpendicular to
delivery
FDA 510(k) cleared
for cobalt systems;
treated patients
since 2014 on
cobalt system
ART capabilities include
1. Shifting plan to overlay
anatomydcouch shift
2. Offline ART
3. Library of plans
4. Online ARTdsegment-
weight optimization and full
reoptimization available
5. Tracking with exception
gating for target
ViewRay MRIdian
Linac system
Newer system with 6-MV
linac, split magnet 70-cm
bore “Razor” MLC is a
double-stacked, double-
focused MLC, 8-mm leaf
width, providing 4-mm
resolution and allowing
field sizes down to
2  4 mm
B0 magnetic field
perpendicular to
delivery
FDA 510(k) cleared
for linac system;
treated patients
since 2017 on
linac system
ART capabilities include
1. Shifting plan to overlay
anatomydcouch shift
2. Offline ART
3. Library of plans
4. Online ARTdsegment-
weight optimization and full
reoptimization available
5. Tracking with exception
gating for target
Sydney Inline
Australian
MRI-LINAC
system (31)
1.0 T 6-MV 82-cm open
bore
B0 magnetic field
perpendicular and
parallel to delivery
Currently, a research
system
NA
MagnetTx Aurora
RT Linac-MR (32)
0.5 T, 6-MV B0 magnetic field
parallel to delivery
Currently, a research
system
NA
Abbreviations: ART Z adaptive radiation therapy; FDA Z Food and Drug Administration; linac Z linear accelerator; MR Z magnetic resonance;
MRI Z magnetic resonance imaging; MV Z megavoltage; NA Z not available; SSD Z solid-state drive.
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can be accounted for and mitigated through Monte Carlo dose
calculations and inverse planning techniques.Benefits and Challenges of MRI
MRI in RT planning provides superior soft tissue dif-
ferentiation with the added capability of functional im-
aging. Improved image contrast has also been
demonstrated with MRgRT systems, with which even
low field strength from an on-board 0.35 T MRI can give
improved anatomic visualization compared with on-
board CT (41), with a reduction in radiation exposure.
Figure 2 shows clinical true fast imaging with steady-state precision MR sequence from ViewRay MRIdian
system of the prostate.
MRI sequences could also be used as an indicator of tumour
response. Some preliminary results of DWI with MRgRT have
been reported (42), although, currently, no validated MRI
biomarkers are available for prostate RT. MR images acquired
throughout a course of MRgRT could allow the dose distri-
bution to be adjusted based on the tumor response. Adaptive
dose painting can target the index lesion, where local relapse is
most likely to occur (14, 20), or areas of more aggressive
disease (18, 19). Currently, a paucity of data assessing imaging
changes during and directly after treatment is available; how-
ever, studies have shown that the apparent diffusion coefficient
values from DWI increase after treatment (43-45), with the
greatest changes seen in patients with better outcomes (44).
Volume 100  Number 2  2018 MR-guided adaptive RT for prostate treatment 365The integration of MRI into the different stages of RT from
target identification to planning to delivery is clearly attrac-
tive. However, limitations exist, including the limited avail-
ability of MRI scanners, medical contraindications to MRI,
and the relatively reduced familiarity with MRI by radiation
oncologists compared with CT. In addition, MRI introduces
technical hurdles within the planning process, including the
lack of direct electron density information, organ motion
between the CT and MRI scans, and geometric distortion.
Conventional immobilization with MR receiver coils presents
additional challenges. Obstacles also include culture changes
when a radiation oncology department houses an MRI scan-
ner. Although integration of MR simulators is becoming more
commonplace in radiation oncology departments, the need to
incorporate MRI safety poses unique challenges.
Daily Adaptive Replanning
Benefits of Daily Adaptive Replanning
With standard IGRT, no method is available to compensate
for the independent movements of the 4 potential RT tar-
getsdprostate, seminal vesicles, pelvic lymph nodes, and
intraprostatic boost. RT can induce an initial increase in the
size of the prostate, followed by constriction at the end of
RT (46, 47). With SBRT, the swelling can persist even after
the end of treatment (48).
Despite daily IGRT to compensate for interfraction
movement, residual deformation of the prostate and the
organs at risk (OAR) (47, 49) with ongoing intrafraction
motion of the prostate continues to be a challenge (50).
Offline adaptation can adjust for systematic changes;
however, Peng et al (51) showed that when the original
treatment plan is superimposed on daily in-room CT
scans, approximately one-third of the fractions wouldFig. 2. A clinical true fast imaging with steady-state
precision magnetic resonance sequence from ViewRay
MRIdian system with acquisition in 25 seconds.need online replanning owing to the discrepancy in the
planned and delivered dose.
The implications of this disparity become more significant
with a shorter ultrafractionated treatment course. On-table,
online ART is now feasible with MRgRT and represents an
attractive solution for ultrahypofractionated prostate RT. On-
line ART has the ability to account for not only systematic
anatomic changes of prostate swelling, but also random
anatomic changes, such as inter- and intrafraction bladder and
rectal filling, in addition to independent movement and defor-
mation of multiple targets.
Daily Adaptive ReplanningdObstacles and Solutions
The solution for optimal delivery of a planned dose is real-
time planning and daily online adaptation. A number of
steps are involved in using the newly acquired images to
adjust for changes in anatomy (Fig. 3).
We have defined 6 strategies for ART:
1. Shifting the plan to overlay anatomy: The dose is
adapted by shifting the plan relative to the anatomy (3-
dimensional or 6-dimensional correction) or vice versa.
This is equivalent to standard IGRT.
2. Dynamic shifting of a plan with tracking: This re-
quires intrafraction motion monitoring and has been
shown to be feasible with prostate cancer with Calypso
beacons (52).3. Offline ART: This is correct for systematic deformations
of the targets (53) or OARs that occur slowly during the
RT course, plus shifting the plan on the day of treatment as
in strategy 2.
4. Library of plans: Selection is from plans for varying
patient anatomy and to deliver the best fit for the anat-
omy of the day (54, 55).
5. Online ART: This is used to adapt the plan on a daily
basis after imaging and to re-optimize or create a new
treatment plan.
6. Real-time (intrafraction) ART: This is used to adapt the
planned dose during an RT fraction.
The strategies most relevant to prostate MRgRT (strat-
egies 1, 5, and 6) are discussed in the subsequent sections
and summarized in Figure 4. The offline strategies 3 and 4
can be performed in lieu of strategy 5, when departmental
resources limit the ability to perform on-table ART. All 6
strategies can be used with MRgRT gating in the presence
of accurate beam-on imaging.
Shifting the Plan to Overlay Anatomy
IGRT repositioning
Online approaches (56) adjust for interfraction displace-
ments of 1 selected RT target using a couch shift technique
and keeping the treatment plan the same.
Simple dose shift
The pretreatment dose distribution itself is translated and
rotated according to the change in anatomy (57). This
Pre-treatment planning image
New images acquired prior to or during
fraction of treatment 
Image registration and
comparison of images
Contour propagation using deformation vector
Editing of new contours
Patient repositioned and/or new
treatment plan generated-see Figure 4
Delivery of ART treatment plan
Deformable registration:
To account for changes in shape
and size
Rigid registration:
Using landmarks e.g. bony landmarks,
fiducials
Fig. 3. Flow chart summarizing the steps in adaptive radiation therapy (ART).
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therefore a rapid IGRT solution. A similar method has been
described for online rotational correction by adjusting the
gantry and collimator angles (58).
Real-time imaging with gated delivery
The challenge of intrafraction motion can be mitigated
using gating strategies, whereby tumor motion monitoring
is used in conjunction with visual inspection or an auto-
mated algorithm to adjust treatment delivery. “Exception
gating” uses a specified threshold, eg, with a 2-mm/5-s
threshold, if the movement of the prostate exceeds 2 mm
from baseline for >5 seconds, treatment delivery is paused
to allow for a return of the prostate to the initial position,
adaptation of patient position, or a simple dose shift.
At present, prostate motion can be monitored using x-ray
tracking of implanted radiopaque markers (seeds) (59, 60) orthe Calypso system using electromagnetic transponders (52).
MRgRT using soft tissue matching, however, does not require
the implantation of seeds or additional radiation exposure and
allows visualization of target and normal tissue motion and
deformation. The accuracy of target localization is dependent
on the speed of image acquisition. Gating through MRI in a
clinical setting has been demonstrated with the MRIdian
system, where motion monitoring is performed on a sagittal
plane acquired at 4 frames per second, followed by real-time
deformation and segmentation of the region of interest (61).
However, this would be further improved using 3D imaging
and patient individualization of the threshold margin, which
might include motion prediction algorithms (62).Online adaptive replanning
A number of methods with various levels of complexity are
available for adaptive replanning. Most studies to date have
Original Planning CT ±
Planning MR
Comparison of new images to original planning image
Online: adaptive replanning
Online: shifting the
plan to overlay
Real-time: motion
monitoring and gating
Real-time: adaptive
re-planning
Images of the
day
Patient
repositioning/
couch shift
Aperture
shift/Simple dose
shift (57)
1.
2.
Use of deformation
field
Adjustment to new
target outline
Interactive dose
manipulation 1.
1.1.
1.
Segment aperture
morphing (SAM) to
create new
apertures +/-
segment weight
optimization (SWO)
(72)
2.
2.
2.
2.
3.
Deform 2D intensity
distribution of each
beam and transform
to new leaf sequences
(66)
Convert to 2D vector
for each beam and
transform beam
apertures (67)
Deform original dose
distributions to
create new ‘goal’
distribution then re-
optimize (65)
Create rings around
target to maintain
dose gradients (68,
69)
4.
3.
X-ray tracking with
radio-opaque
markers (59, 60)
Tracking with
electromagnetic
transponders (52)
Adaptive Sequencer
(ASEQ) to re-plan
according to ideal
dose distribution
(78)
MLC tracking and
dose accumulation
(79-81)
1.
2.
Real-time
interactive planning
(RTIP) using
achievable dose
estimate (ADE)
(74)
Interactive dose
shaping (IDS) using
dose modification
and recovery
(DMR) (76)
MR-tracking of
region of interest
with real-time
deformation and
segmentation (61)
Modification of MLC
leaf position for each
subfield and calculate
new dose
distribution (70)
Fig. 4. Flow chart summarizing the spectrum of adaptive radiation therapy (ART). Abbreviations: CT Z computed to-
mography; MLC Z multileaf collimator; MR Z magnetic resonance.
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poorer image quality (compared with planning CT and
MRI) for new contours, followed by plan adaptation.
The “Blue Sky” aim would be eventually to dispense
with pretreatment planning completely and create an online
plan from the beginning each day to reflect the current
anatomy. This can be in tandem with dose painting based
on the distribution of the tumor load as described previ-
ously (63). Online MRgRT has been demonstrated clini-
cally with daily MRI by reoptimizing using the original
beam angles and objectives used if the constraints were not
met (64). Just greater than one-half of the fractions were
treated using an adapted plan. The median time for ART
was 26 minutes and was well tolerated.
Because this process needs to be completed in a timely
manner, several approaches have described adjusting the
initial plan, without full optimization, for expediency.
Rapid replanning is especially important because increased
organ motion over time could negate any benefit from ART.
Use of the deformation field
The deformation matrix created by registering the daily
verification images to the planning images can be used toalter the original plan accordingly. Comparison of the
whole target or points on the target (65) in the beam’s eye
view can be used to modify each segment (66) or beam
aperture (67). Alternatively, the method of gradient main-
tenance (68) creates a series of partial concentric rings
around the target with the aim of retaining the dose gra-
dients toward each OAR. A similar method has been
described with the MRIdian system, whereby rings control
the gradients and autosegmentation through deformation, to
minimize the recontouring required (69).
Adjustment to new target outline
To avoid the complexities of deformable image registration
(DIR), methods to simply compare the target outline are
available (70, 71). Segment aperture morphing can adjust the
segment shapes to the new target contour (72), with a further
step of segment weight optimization for larger deformations.
Online replanning methods that are suitable for implementa-
tion with the Elekta MR-Linac have also been reported
(71, 73).
Interactive dose manipulation
This approach enables the clinician to use tools to click on
or select a part of the plan and “drag” the isodose curves or
Pathmanathan et al. International Journal of Radiation Oncology  Biology  Physics368dose-volume histogram and view the updated dose distri-
bution (74-76). Constraints can be defined that should not
be violated, to preserve, for example, a minimum dose to
the target (74). In the future, these could allow for real-time
automated modification of a plan to the anatomy of the day
both before and during treatment.Real-time adaptive replanning
The methods described so far have mainly focused on the
target outline alone, and although they can improve target
coverage compared with patient repositioning alone (66,
67, 70), ultimately replanning from the beginning will
yield the best dosimetry. Real-time ART can improve dose
accuracy, regardless of the delivery system (77). The only
way this can be achieved is by continuous imaging with
constant replanning, including reoptimization. Treatment
planning systems are already capable of rapid dose calcu-
lations using cloud computing.
The ultimate goal of adaptive replanning will be to adapt
a plan during beam delivery. Kontaxis et al (78) have
described a graphics-processing unit, Monte Carlo dose
engine, inverse dose optimization algorithm, and an adap-
tive sequencer to calculate deliverable intensity modulated
RT plans. New images are fed into this system in real time.
Starting with an ideal dose, the sequencer calculates each
segment and the dose that it will deliver, subtracting this
from the initially calculated “ideal” dose distribution. This
step is repeated with multiple iterations to achieve the ideal
dose. Treatment can start before the final dose calculation is
complete, allowing the constantly changing anatomy to
affect the optimization and preventing a delay in treatment.
At the end of each fraction, the actual dose delivered is
used to calculate any excess in dose or shortfall, which is
then compensated for by adjusting the dose calculations in
the subsequent fractions.
Real-time multileaf collimator tracking has been
demonstrated to improve dose delivery in a clinical setting
for prostate patients using the Calypso localization system
(79). If accurate online dose reconstruction is available, this
can provide a rapid calculation of the dose delivered so far
within a fraction to adjust the dose for the remaining
fraction delivery time and allow intrafraction replanning.
This has been described for dynamic multileaf collimator
tracking (80) and can be used to reoptimize a plan in the
time taken for the gantry to rotate between beams for un-
interrupted treatment (81).
Although such solutions are attractive, they assume that
DIR is a well-solved problem. However, the bladder,
rectum, and prostate deform in a nonuniform manner. This
makes the quality assurance of accurately documenting the
delivered dose challenging, and novel methods of time-
efficient quality assurance are required (82).
Before adaptive intrafraction replanning becomes a re-
ality, efforts are currently focused on expediting imaging,
replanning and beam-on times such that intrafraction
adaptation is not required.Autosegmentation
Benefits of autosegmentation
Having a clinician recontour a patient in real time as a part
of an adaptive workflow is not feasible on a daily basis. The
advantages of autosegmentation are a reduction in the time
required for delineation and decreased interobserver vari-
ability (83, 84). For real-time ART, autosegmentation will
allow rapid replanning using real-time images, ultimately
without the need for a clinician to be present.Obstacles to autosegmentation and solutions
Multiple methods are available for autosegmentation, with
the most basic techniques using features of imaging alone
such as grayscale measures to create contours. However,
the more sophisticated, rapidly evolving automated atlas-
based segmentation software uses a pre-existing library of
contoured reference atlases to automatically generate con-
tours on a new set of images using rigid image registration
or DIR. Multiple-atlas methods such as simultaneous truth
and performance level estimation (85) and majority vote
create autocontours from a number of fused atlases and are
therefore more accurate than single-atlas methods. Greater
weighting can be given to the atlases chosen by the soft-
ware to have anatomy most similar to the plan in question.
The optimal number of atlases required will vary depending
on the software used and the structure to be delineated.
Although additional atlases provide more comprehensive
anatomic data, this is with the computational cost of
additional time and the accuracy of the autocontour plateau
with increasing atlas numbers (86).
The level of agreement between manually drawn con-
tours and autocontours is dependent on the target volume.
For prostate RT planning, good concordance has been seen
for structures such as the femoral heads and bladder (86-88)
and poor concordance for seminal vesicles and the penile
bulb. Variable results have been seen for accuracy of
prostate definition with CT; however, as expected, this
improves when MRI is used for autodelineation (89, 90).
MRI optimization, such as sequences improving the visu-
alization of the prostate capsule, might further improve
autocontouring (Fig. 5; PACE trial MRI sequence).
Although potential exists for these programs to improve
efficiency, the current limitation result from the huge
variability in pelvic anatomy and the poor soft tissue
contrast previously seen with various CT modalities
(91, 92). In the first case, review and editing of any auto-
contours are required (93, 94).
Segmentation for target tracking must be both rapid and
accurate but will depend on image contrast, MR field
strength, and the method of autosegmentation used (95).
For atlas-based methods with real-time intrafraction seg-
mentation, the reference atlas is patient-specific and DIR
Fig. 5. Magnetic resonance image using adaptation of the
“medic” T2-weighted Siemens sequence showing prostate
capsule and fiducial markers (image courtesy of Maria
Schmidt, Institute of Cancer Research).
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curate (84, 96, 97) and time efficient.MRI-Only Workflow
Benefits of MRI-only workflow
RT planning currently uses CT imaging, which provides the
relevant electron density required for dose calculations. A
mixed CT-MRI workflow requires image coregistration,
which incurs the risk of introducing inaccuracy as a result
of discrepancies in patient positioning, imaging informa-
tion, and anatomic changes between scans. The latter is
particularly relevant for prostate cancer patients, in whom
bladder and rectal filling can vary between scans, although
minimizing the time between CT and MRI acquisitions can
reduce this problem.
The registration error has been estimated to be approx-
imately 2 mm (98) and remains a problem even when using
gold fiducial markers to coregister the CT and MRI scans
(99), although the “real truth” of image registration inac-
curacy is unknown. However, the ultimate goal of the
MRgRT system would be to avoid the need for fiducial
markers, which require extra resources for insertion and
have associated risks for the patients.
Planning directly on an MRI scan removes the system-
atic error of coregistration (100), which might be large
enough to counteract any advantage from the addition of
MRI into the process. MRI-only workflow requires a syn-
thetic CT or pseudo-CT scan (101, 102) to give the electron
density information required for dose calculations. A major
challenge when using MRI is geometric distortion, which
can result from either machine-related or patient-related
factors. Geometric distortion is greater at a distance fromthe center of the field; however, for accurate dose calcu-
lation, the spatial integrity maintained to the skin surface is
essential. This should be minimized using postprocessing
before the use of images for planning (102). Efforts have
been made to characterize correction maps; however,
further work is needed to quantify and develop methods for
mitigating geometric distortion (103).
Obstacles to MRI-only workflow and solutions
A number of methods are available to create a pseudo- or
synthetic CT scan. These include tissue segmentation, atlas
mapping method, and voxel method.
Tissue segmentation
After manual or automatic segmentation of an MRI data
set, assigning separate densities to air, soft tissue, and bone
is more accurate than applying a single electron density
equivalent to water to the whole body (104, 105) and gives
comparable results to the standard method of a planning CT
scan (105, 106). However, bone segmentation is time
consuming using standard MRI sequences, and the value
used for the assigned densities must also be relevant (105,
107, 108).
Atlas mapping method
The first step for the atlas mapping method (109, 110) in-
volves the generation of MRI and pseudo-CT atlases from
patient data. When MRI data from a new patient is ac-
quired, the same deformations required to register the
compiled MRI atlas to the new MR images are applied to
the pseudo-CT atlas to map the electron density information
to the new patient. A comparison of the standard planning
CT scan to the pseudo-CT scan gave a dose difference of
<2% (109, 111), in agreement with data from other MRI
planning studies (104, 112). This method can also be used
to propagate contours (109, 110); however, it does have
limitations, with atypical patient anatomy and the initial
step of atlas formation requiring DIR, with the potential
errors as described in previous sections.
Voxel method
Statistical models to differentiate the attenuation of tissue
types have been investigated to allow the automatic con-
version of the MRI intensity in each voxel to a Hounsfield
unit (113-115). Using the information from all voxels, a
greater spectrum of attenuation coefficients is obtained for
a more accurate dose calculation, rather than the limited
number used with tissue segmentation (115, 116).
Ultimately, an automated approach for pseudo-CT gen-
eration, combining the described methods, will be more
clinically useful. The now commercially available Philips
MRCAT (MR for calculation attenuation) creates a pseudo-
CT scan from an mDIXON sequence, acquired with 2 echo
times. The initial step comprises model-based automatic
tissue segmentation into the 5 classes of air, fat, water-rich
tissue, spongy bone, and compact bone. In the second step,
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based on density values. A number of factors contribute to
dose calculations in this process (117); however, the
workflow appears to be dosimetrically accurate compared
with CT-based planning (118) and has been implemented
clinically in prostate RT (119).
MRI-only workflow is now a realistic prospect in the
near future and could improve the accuracy of RT planning.
Conclusions
The technological revolution in RT planning now allows us
to ask questions, which a decade ago would have been
impossible to answer. The increased precision in every step
might allow us to further hypofractionate prostate cancer
RT, perhaps even down to a single fraction, such as has
been demonstrated with brachytherapy. Although this could
be delivered using CT guidance, the ideal technology
would be MRgRT. Intrafraction MRI, automatic contour-
ing, and fast online and real-time adaptive replanning allow
us to challenge the accepted dogma of the RT planning
workflow.
To achieve this vision, many hurdles lie ahead, and high
quality clinical research is necessary. The challenges are
clear and the benefit is yet to be realized. As a wise man
once said, “a journey of a thousand miles starts with a
single step.”References
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